Polaris Wealth Advisory Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Polaris Wealth Advisory Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-44,728	Closed	-$3.44M	–	181
2020 Q3	$3.44M	Buy	+44,728	New	+$4.53M	0.32%	77
2018 Q4	–	Sell	-60	Closed	-$6K	–	175
2018 Q3	$6K	Buy	+60	New	+$5.99K	﹤0.01%	435
2018 Q2	–	Sell	-60	Closed	-$5K	–	267
2018 Q1	$5K	Buy	+60	New	+$5.15K	﹤0.01%	401

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Polaris Wealth Advisory Group's BMRN Position: Q4 2020 in Review

Polaris Wealth Advisory Group sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2020, closing a stake of 44,728 shares — an estimated $3.44M sold.

Polaris Wealth Advisory Group first reported a position in BMRN in Q1 2018 and held it in 3 quarters. The position peaked at $3.44M in Q3 2020. 537 funds tracked by Wall St. Rank hold BMRN as of Q4 2020.

Polaris Wealth Advisory Group reported no remaining BioMarin Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Polaris Wealth Advisory Group sold 44,728 BioMarin Pharmaceuticals shares in Q4 2020, an estimated $3.44M.
Polaris Wealth Advisory Group first reported a position in BioMarin Pharmaceuticals in Q1 2018 and held it in 3 quarters.
Polaris Wealth Advisory Group's BioMarin Pharmaceuticals position peaked at $3.44M in Q3 2020.
537 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2020.

Based on Polaris Wealth Advisory Group's 13F filing for Q4 2020, filed 25 Jan 2021.